• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Jia Dengyao

    10/1/25 1:24:47 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ESLA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jia Dengyao

    (Last) (First) (Middle)
    5858 HORTON STREET, SUITE 370

    (Street)
    EMERYVILLE, CA 9460

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/22/2025
    3. Issuer Name and Ticker or Trading Symbol
    Estrella Immunopharma, Inc. [ ESLA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Dengyao Jia 10/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ESLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESLA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ESLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

    Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The oral presentation highlighted clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the ST

    2/9/26 7:00:00 AM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

    Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The presentation will highlight clinical data from the Company's ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Estrella's late-breakin

    2/3/26 8:00:00 AM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

    Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW)) (the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company's common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock. The combined offering price for each share of common stock and accompan

    1/6/26 2:02:00 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ESLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Jia Dengyao

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/1/25 1:24:47 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Executive Officer Liu Cheng

    4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    2/14/25 4:30:20 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Xu Jiandong

    4 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    2/14/25 4:30:12 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ESLA
    SEC Filings

    View All

    SEC Form 424B3 filed by Estrella Immunopharma Inc.

    424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/13/26 5:28:29 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Estrella Immunopharma Inc.

    EFFECT - Estrella Immunopharma, Inc. (0001844417) (Filer)

    1/26/26 12:15:19 AM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form S-1/A filed by Estrella Immunopharma Inc.

    S-1/A - Estrella Immunopharma, Inc. (0001844417) (Filer)

    1/21/26 8:51:59 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ESLA
    Leadership Updates

    Live Leadership Updates

    View All

    Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

    Estrella Immunopharma, Inc. (NASDAQ:ESLA, ESLAW))) ("Estrella", "Estrella Immunopharma", or the "Company"), a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases, today announced the appointment of Hong Zhang as Chairperson and a member of its Board of Directors. This appointment comes shortly after the Company dosed the first patient in its Phase I/II clinical trial (STARLIGHT-1) for EB103, an autologous T-cell therapy for adult patients with relapsed or refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL). Ms. Zhang's appointment increases the size of Estrella's Board from five to six dire

    8/14/24 12:00:00 PM ET
    $ESLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care